The company reported strong clinical efficacy data with 64% of patients maintaining clinical remission at 52 weeks, meaningful histologic improvements, excellent safety profile with no serious adverse events or common steroid-related side effects, and potential for annual dosing regimen. These results support advancement toward Phase 2b and suggest the drug candidate has significant therapeutic potential for EoE treatment.
Strong shareholder support demonstrated by high voting percentages for all board nominees (91-99.97%), successful completion of AGM, and ongoing clinical development programs with positive trial results (EP-104IAR met primary endpoint in Phase 2b trial). Company has secured $63.2 million in funding to advance clinical trials.
The company is presenting multiple clinical abstracts at a major medical conference with data showing persistent improvements in histological features over 36 weeks. This demonstrates progress in their lead candidate EP-104GI and provides visibility to the medical and investor community, which is typically viewed positively for clinical-stage biotech companies.
The company reported strong clinical efficacy data with 90% reduction in tissue inflammation markers, 72% reduction in eosinophil counts, and 66% clinical remission rate. Additionally, the drug demonstrated excellent safety profile with no serious adverse events across 230+ patient-months of follow-up and no cases of common steroid-related side effects. These positive Phase 1b/2a results support advancement to Phase 2b trials with top-line data expected in Q4 2026.
The company achieved significant clinical milestones with positive tissue health data from the RESOLVE trial, successfully closed a $63.2 million public offering, and strengthened its balance sheet with extended cash runway to mid-2028. These developments support advancement of its pipeline and next phase of growth, despite increased operating losses typical for clinical-stage biotech companies.
Articles that tag EPRX but are mainly about other companies.
EP-104GI, a glucocorticoid receptor agonist with once-yearly submucosal injection, demonstrated positive tissue health data in Phase Ib/IIa RESOLVE trial, offering innovative delivery addressing treatment adherence challenges.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
